ArticleEpidemiology and infection2021
Large increase of vertebral osteomyelitis in France: a 2010-2019 cross-sectional study.
Article in Epidemiology and infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Rifampin Based Therapy for Patients With Staphylococcus aureus Native Vertebral Osteomyelitis: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Pooled it
- Continuous local antibiotic perfusion for spinal infection: a systematic review of reported cases.Journal of spine surgery (Hong Kong) · 2026Review
- Polymethyl Methacrylate (PMMA) Cement as an Interbody Spacer in Pyogenic Spondylodiscitis: Results of a Scoping Review.Global spine journal · 2026Review
- The Incidence, Pathogen Spectrum, and Resistance Profile of Pyogenic Spondylodiscitis: A Nationwide Retrospective Evaluation of G-DRG Data.Deutsches Arzteblatt international · 2026Observational
- Article
- Comparison of Hospital Mortality and Risk Factors in Conservative and Surgical Treatment of Pyogenic Vertebral Osteomyelitis: A Nationwide Analysis of 49,951 Cases in Germany.Global spine journal · 2026Article
- Differentiating Tuberculous and Pyogenic Spondylodiscitis: Part I-Epidemiology, Clinical Features, Laboratory Markers, and Tissue-Based Diagnosis.Diagnostics (Basel, Switzerland) · 2026Review
- Clinical Manifestations, Long-Term Trends, and Risk Factors for Treatment Failure in Native Vertebral Osteomyelitis: A 26-Year Mayo Clinic Experience.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- The MSI-20 Score Provides Reproducible Mortality Risk Stratification in Spinal Infection: A Multicenter Registry Study and External Validation.Neurospine · 2026Article
- External Validation of the SITE Score for De Novo Spinal Infections: A Retrospective Cohort Study.Global spine journal · 2026Article
- Osteomyelitis.Nature reviews. Disease primers · 2026Review
- Infectious Spondylodiscitis of Bacterial Causes in Adults: Epidemiology, Pathophysiology, Diagnostic and Treatment Challenges.Microorganisms · 2026Review
- Clinical characteristics, management, and outcome of vertebral osteomyelitis with known versus unknown aetiology: a single-centre retrospective study between 2017-2023.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Spinal infections.Frontiers in neuroscience · 2026Review
- Clinical features of pyogenic vertebral osteomyelitis and factors associated with adverse clinical outcome: a retrospective cohort study.BMC infectious diseases · 2025Article
- Pyogenic Spondylodiscitis: Predictors of Microbiological Yield from Biopsy in a Tertiary Hospital.Medicina (Kaunas, Lithuania) · 2025Article
- What Is Worse: A Comparison of Solitary Versus Multifocal Pyogenic Spondylodiscitis Using a Nationwide Analysis of Readmission Rates and Risk Factors.Journal of clinical medicine · 2025Article
- Vertebral osteomyelitis in patients with an underlying malignancy or chronic kidney disease - who is at higher risk for adverse outcome?Infection · 2025Article
- An Assessment of C-Reactive Protein and Erythrocyte Sedimentation Rate in Ruling Out Acute Infectious Spinal Pathology in Emergency Department Patients: A Retrospective Cohort Study.Journal of the American College of Emergency Physicians open · 2025Article
- The conundrum of finding an optimal spondylodiscitis treatment pathway: how do treatments affect readmission rates?European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vertebral osteomyelitis (VO) represents 4-10% of bone and joint infections. In Western countries, its incidence seems to increase, simultaneously with an increasing number of comorbidities among an ageing population. This study aimed to assess the evolution of VO epidemiology in France over the 2010-2019 decade. A nationwide cross-sectional study was conducted using the French hospital discharge data collected through the French diagnosis-related groups 'Programme de Médicalisation des Systèmes d'Information'. VOs were detected with a previously validated case definition using International Classification of Diseases 10 (ICD-10) codes, implemented with the French current procedural terminology codes. The study population included all patients hospitalised in France during the 2010-2019 decade, aged 15 years old and more. Patient and hospital stay characteristics and their evolutions were described. During the study period, 42 105 patients were hospitalised for VO in France involving 60 878 hospital stays. The mean VO incidence was 7.8/100 000 over the study period, increasing from 6.1/100 000 in 2010 to 11.3/100 000 in 2019. The mean age was 64.8 years old and the sex ratio was 1.56. There were 31 341 (74.4%) patients with at least one comorbidity and 3059 (7.3%) deceased during their hospital stay. Even if rare, device-associated VOs (4450 hospital stays, 7.3%) highly increased over the period. The reliability of the method, based upon an exhaustive database and a validated case definition, provided an effective tool to compare data over time in real-life conditions to regularly update the epidemiology of VO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.